A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

NCT02413580 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Myasthenia Gravis Exacerbations

Interventions

BIOLOGICAL: IGIV-C

Sponsor

Grifols Therapeutics LLC